Garg Pushkal (CIK 1829252) reported 140 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-03-06). Recent activity: Sell ALNY (106 shares), Sell ALNY (102 shares), Sell ALNY (215 shares), Sell ALNY (289 shares), Sell ALNY (350 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 106 | $33,817 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 102 | $32,641 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 215 | $68,974 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 289 | $93,006 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 350 | $113,054 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 767 | $248,385 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 272 | $88,367 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 208 | $67,739 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 654 | $210,804 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 740 | $239,427 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 510 | $165,541 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 500 | $163,040 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Buy | 4,769 | $0 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 50 | $16,181 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 97 | $31,491 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 277 | $90,200 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 421 | $137,587 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 353 | $115,668 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 107 | $35,172 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 182 | $60,007 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 87 | $28,784 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 101 | $33,525 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 42 | $13,971 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 355 | $112,443 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP Chief R&D | Sell | 317 | $101,142 |
Source: SEC Form 4 filings · as of 2026-03-06